血清胃蛋白酶原、胃泌素17和幽门螺杆菌IgG抗体在胃部疾病初筛中的临床价值

doi:10.16150/j.1671-2870.2022.04.015

摘要/Abstract

摘要：

目的：探究血清胃蛋白酶原Ⅰ（Pepsinogen Ⅰ,PGⅠ）、PGⅡ以及PGⅠ/PGⅡ比值、胃泌素17（Gastrin-17,G-17）和幽门螺杆菌（Helicobactor pylori,Hp）-IgG抗体检测在临床胃部疾病初筛中的价值。方法：选取2018年7月至2020年7月因胃部疾病于我院消化科住院行胃镜检查者300人为研究对象,根据胃镜及病理检查结果分为慢性浅表性胃炎组、慢性萎缩性胃炎组、胃癌组、胃溃疡组,并抽取同期体检中心健康体检者100人作为对照组,比较各组间的血清PGⅠ、PGⅡ、PGⅠ/PGⅡ比值、G-17水平及Hp-IgG抗体阳性率情况。结果：血清PGⅠ/PGⅡ比值在胃癌组（10.42±4.63）及慢性萎缩性胃炎组（10.54±4.36）中均低于对照组（12.07±6.80）,血清G-17水平在胃癌组[（13.85±27.68） pmmol/L]及慢性萎缩性胃炎组[（9.63±10.82） pmmol/L]中均高于对照组[（6.02±7.30） pmmol/L],血清PGⅠ水平在胃癌组[（123.53±35.45） μg/L]中低于对照组[（148.24±83.85） μg/L]及慢性浅表胃炎组[（141.95±81.11） μg/L],差异均有统计学意义（P均<0.05）。Hp-IgG抗体阳性率在胃癌组（50.75%）及慢性萎缩性胃炎组（50.00%）中均高于对照组（35.00%）,差异有统计学意义（P均<0.05）。结论：血清PGⅠ、PGⅡ、PGⅠ/PGⅡ、G-17及Hp-IgG抗体检测可用于胃部疾病的初筛,以便发现胃癌高危人群,为进一步筛查胃癌提供可靠参考。

关键词: 胃癌筛查, 胃蛋白酶原, 胃泌素17, 幽门螺旋杆菌IgG抗体

Abstract:

Objective: To explore the clinical value of serum PGI, PGII, PGI/PGII, G-17 levels and Hp-IgG antibody in the preliminary screening of gastric diseases. Methods: A total of 300 patients who underwent gastroscopy in the Gastroenterology Department of our hospital from July 2018 to July 2020 due to gastric diseases were selected as the research objects. According to gastroscopy and pathological examinations, they were divided into chronic superficial gastritis group,chronic atrophic gastritis group and gastric cancer group. 100 healthy patients from the physical examination center during the same period were selected as the control group. The serum PGI, PGII, PGI/PGII G17 levels and the positive rate of Hp-IgG antibody in each group were compared. Results: Serum PGI/PGII levels in gastric cancer group(10.42±4.63) and atrophic gastritis group (10.54±4.36) were lower than those in control group (12.07±6.80). Serum G-17 levels in gastric cancer group [(13.85±27.68） pmmol/L] and chronic atrophic gastritis group [(9.63±10.82) pmmol/L] were higher than those in control group [(6.02±7.30) pmmol/L]. The serum PGI level in gastric cancer group[(123.53±35.45) μg/L] was lower than that in the control group[(148.24±83.85) μg/L and chronic superficial gastritis group [(141.95±81.11) μg/L]. The differences were statistically significant (P<0.05). The positive rate of Hp-IgG antibody in gastric cancer group (50.75%) and atrophic gastritis group (50.00%) was higher than that of the control group (35.00%), and the difference was statistically significant (P<0.05). Conclusions: Serum PGI, PGII, PGI/PGII, G-17 levels and Hp-IgG antibody detection can be used for the primary screening of gastric diseases, which can identify high-risk groups of gastric cancer and provide a reliable reference for further screening of gastric cancer.

Key words: Gastric cancer screening, Pepsinogen, Gastrin-17, Helicobacter pylori IgG antibody

中图分类号:

R730

李娜娜, 齐涛, 朱黎明. 血清胃蛋白酶原、胃泌素17和幽门螺杆菌IgG抗体在胃部疾病初筛中的临床价值[J]. 诊断学理论与实践, 2022, 21(04): 509-513.

LI Nana, QI Tao, ZHU Liming. Clinical value of serum pepsinogen,gastrin 17 and Helicobacter pylori IgG antibody in primary screening of gastric diseases[J]. Journal of Diagnostics Concepts & Practice, 2022, 21(04): 509-513.

图/表 2

参考文献 21

[1]	刘茜羽, 张孟, 于庆功. 慢性胃病临床特点及胃蛋白酶原联合胃泌素17临床诊断价值分析[J]. 世界最新医学信息文摘(连续型电子期刊), 2019, 19(71):54-56.
	Liu QY, Zhang M, Yu QG. Clinical Characteristics of Chronic Gastric Diseases and Clinical Diagnostic Value of Pepsinogen Combined with Gastrin 17[J]. World Latest Med Inform, 2019, 19(71):54-56.
[2]	高雪艳, 冯义朝. 血清胃蛋白酶原水平在胃部疾病中的临床应用及意义[J]. 世界最新医学信息文摘(连续型电子期刊), 2016, 16(50):53-54.
	Gao XY, Feng YC. Clinical application and significance of serum pepsinogen level in gastric diseases[J]. World Latest Med Inform, 2016, 16(50):53-54.
[3]	周勃. 血清胃蛋白酶原在临床胃部疾病中的研究进展[J]. 继续医学教育, 2021, 35(11):128-130.
	Zhou B. Research progress of serum pepsinogen in clinical gastric diseases[J]. Contin Med Educ, 2021, 35(11):128-130.
[4]	Mansour-Ghanaei F, Joukar F, et al. Only serum pepsinogen I and pepsinogen Ⅰ/Ⅱ ratio are specific and sensitive biomarkers for screening of gastric cancer[J]. Biomol Concepts, 2019, 10(1):82-90. doi: 10.1515/bmc-2019-0010 pmid: 31188744
[5]	甘建, 程荣贵, 王韶峰. 血清胃蛋白酶原对胃部疾病的诊断价值[J]. 世界华人消化杂志, 2018, 26(36):2115-2119.
	Gan J, Chen RG, Wang SF. Diagnostic value of serum pepsinogen in gastric diseases[J]. World Chin J Digestology, 2018, 26(36):2115-2119. doi: 10.11569/wcjd.v26.i36.2115 URL
[6]	刘兰凤, 杜丽新, 刘海燕, 等. 血清胃蛋白酶原检测在诊断胃部疾病中的应用价值[J]. 当代医药论丛, 2018, 16(21):167-168.
	Liu LF, Du LX, Liu HY, et al. Application value of serum pepsinogen detection in the diagnosis of gastric diseases[J]. Contemp Med Forum, 2018, 16(21):167-168.
[7]	Miki K. Gastric cancer screening by combined assay for serum anti-Helicobacter pylori IgG antibody and serum pepsinogen levels - "ABC method"[J]. Proc Jpn Acad Ser B Phys Biol Sci, 2011, 87(7):405-414. doi: 10.2183/pjab.87.405 URL
[8]	Yamaguchi Y, Nagata Y, Hiratsuka R, et al. Gastric Cancer Screening by Combined Assay for Serum Anti-Helicobacter pylori IgG Antibody and Serum Pepsinogen Levels--The ABC Method[J]. Digestion, 2016, 93(1):13-18. doi: 10.1159/000441742 pmid: 26789514
[9]	Watson SA, Grabowska AM, El-Zaatari M, et al. Gastrin - active participant or bystander in gastric carcinogenesis?[J]. Nat Rev Cancer, 2006, 6(12):936-946. pmid: 17128210
[10]	Kikuchi R, Abe Y, Iijima K, et al. Low serum levels of pepsinogen and gastrin 17 are predictive of extensive gastric atrophy with high-risk of early gastric cancer[J]. Tohoku J Exp Med, 2011, 223(1):35-44. pmid: 21222340
[11]	Zagari RM, Rabitti S, Greenwood DC, et al. Systematic review with meta-analysis: diagnostic performance of the combination of pepsinogen, gastrin-17 and anti-Helicobacter pylori antibodies serum assays for the diagnosis of atrophic gastritis[J]. Aliment Pharmacol Ther, 2017, 46(7):657-667. doi: 10.1111/apt.14248 URL
[12]	Tu H, Sun L, Dong X, et al. A Serological biopsy using five stomach-specific circulating biomarkers for gastric cancer risk assessment: a multi-phase study[J]. Am J Gastroenterol, 2017, 112(5):704-715. doi: 10.1038/ajg.2017.55 pmid: 28323271
[13]	Correa P. Human gastric carcinogenesis: a multistep and multifactorial process--First American Cancer Society award lecture on cancer epidemiology and prevention[J]. Cancer Res, 1992, 52(24):6735-6740. pmid: 1458460
[14]	Wang Y, Zhu Z, Liu Z, et al. Diagnostic value of serum pepsinogen I, pepsinogen Ⅱ, and gastrin-17 levels for population-based screening for early-stage gastric cancer[J]. J Int Med Res, 2020, 48(3):300060520914826.
[15]	雷雅莉, 苌新明. 血清胃泌素-17与胃蛋白酶原诊断胃癌价值研究[J]. 人民军医, 2020, 63(5):474-476,487.
	Lei YL, Chang XM. Diagnostic value of serum gastrin-17 and pepsinogen in gastric cancer[J]. People′s Mil Surg, 2020, 63(5):474-476,487.
[16]	朱正其, 赵缜, 曹国君, 等. 早期胃癌患者血清PGⅠ/PGⅡ、G-17及抗-Hp的检测及临床价值探讨[J]. 国际检验医学杂志, 2020, 41(8):996-998.
	Zhu ZQ, Zhao Z, Cao GJ, et al. Detection and clinical value of serum PG Ⅰ /pg Ⅱ, G-17 and anti HP in patients with early gastric cancer[J]. Int J Lab Med, 2020, 41(8):996-998.
[17]	Wang Y, Zhu Z, Liu Z, et al. Diagnostic value of serum pepsinogen I, pepsinogen II, and gastrin-17 levels for population-based screening for early-stage gastric cancer[J]. J Int Med Res, 2020, 48(3):300060520914826.
[18]	Cao XY, Jia ZF, Jin MS, et al. Serum pepsinogen Ⅱ is a better diagnostic marker in gastric cancer[J]. World J Gastroenterol, 2012, 18(48):7357-7361. doi: 10.3748/wjg.v18.i48.7357 URL
[19]	Sugano K. Effect of Helicobacter pylori eradication on the incidence of gastric cancer: a systematic review and meta-analysis[J]. Gastric Cancer, 2019, 22(3):435-445. doi: 10.1007/s10120-018-0876-0 pmid: 30206731
[20]	Lee YC, Chiang TH, Chou CK, et al. Association Between Helicobacter pylori Eradication and Gastric Cancer Incidence: A Systematic Review and Meta-analysis[J]. Gastroenterology, 2016, 150(5):1113-1124,e5. doi: 10.1053/j.gastro.2016.01.028 URL
[21]	袁玉涛. 胃癌早期诊断中血清胃蛋白酶原及幽门螺杆菌抗体的价值分析[J]. 当代医学, 2019, 25(31):107-109.
	Yuan YT. Value of serum pepsinogen and Helicobacter pylori antibodies in early diagnosis of gastric cancer[J]. Contemp Med, 2019, 25(31):107-109.

组别	例数（n）	PGⅠ（μg/L）	PGⅡ（μg/L）	PGⅠ/PGⅡ比值	G-17（pmmol/l）
对照组	100	148.24±83.85	12.87±6.43	12.07±6.80	6.02±7.30
胃溃疡组	40	201.75±78.30	22.81±13.01^b	10.74±5.75	8.32±10.34
慢性浅表性胃炎组	117	141.95±81.11	14.92±10.41	11.66±5.89	7.87±9.72
慢性萎缩性胃炎组	78	131.32±71.92	15.08±11.35^b	10.54±4.36^b	9.63±10.82^b
胃癌组	65	123.53±35.45^ab	14.52±8.56	10.42±4.63^b	13.85±27.68^ab